Immunome, Inc. (IMNM) News
Follow Immunome, Inc. (IMNM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Immunome Acquires Full Patent Rights to Varegacestat, AL101 from BMS
Immunome amended its 2017 license with Bristol-Myers Squibb to acquire full patent rights for varegacestat (formerly AL102) and AL101. In exchange, Immunome paid $20.0 million in cash and issued 4,425,487 common shares,
EQUITY | Oct 05, 2026, 12:33 PM UTC
L
Immunome, Inc. (IMNM) Wins FDA IND Clearance for IM-1340 ADC
Immunome received FDA clearance of its IND for IM-1340, a potential first-in-class ADC for advanced solid tumors, and expects to start a Phase 1 dose-escalation/expansion trial in Q4 2026.Material DetailsContext by AI An
REGULATION | Sep 30, 2026, 11:45 AM UTC
L
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Immunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA
REGULATION | Sep 30, 2026, 11:45 AM UTC
L
HC Wainwright & Co. maintained Immunome $40 price target
MACRO | Sep 10, 2026, 01:43 PM UTC
L
Immunome compensation committee grants inducement under Nasdaq Rule 5635(c)(4)
Immunome, Inc. said its Compensation Committee approved inducement grants under Nasdaq Listing Rule 5635(c)(4) on September 1, 2026.
EQUITY | Sep 08, 2026, 08:02 PM UTC
L
Immunome to present at H.C. Wainwright 28th conference on Sept. 14, 2026
Immunome management will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, according to a company announcement.
EQUITY | Sep 02, 2026, 11:45 AM UTC
L
Immunome Q2 EPS $(0.65) Misses $(0.52) Estimate
Immunome (NASDAQ: IMNM ) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.52) by 25 percent. This is a 30 percent decrease over losses of $(0.50) per share from the same p
EARNINGS | Aug 11, 2026, 08:34 PM UTC
H
SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Wednesday. Shares of Space Exploration Technologies Corp (NASDAQ: SPCX ) fell sharply in pre-market trading after the company
EARNINGS | Aug 05, 2026, 12:03 PM UTC
L
ARGX raise PT slightly to $1182 - IMNM is a high-PoS opportunity @ Citi
ARGX raise PT slightly to $1182 - IMNM is a high-PoS opportunity @ Citi
EQUITY | Jul 21, 2026, 10:41 AM UTC
L
IMNM Immunome announces first patient dosed in phase 1 trial evaluating im-3050, an fap-targeted radioligand therapy, in patients with fap-e
IMNM Immunome announces first patient dosed in phase 1 trial evaluating im-3050, an fap-targeted radioligand therapy, in patients with fap-expressing advanced solid tumors Immunome - phase 1 trial to evaluate safety and
EQUITY | Jul 20, 2026, 11:31 AM UTC
L
Immunome Says FDA Accepted NDA for Desmoid Tumors Drug
() -- Immunome (IMNM) said Wednesday that the US Food and Drug Administration has accepted its new drug application for varegacestat, intended to treat adults with desmoid tumors. The agency assigned a Prescription Drug
REGULATION | Jul 08, 2026, 12:06 PM UTC
L
Immunome's NDA for varegacestat in desmoid tumors accepted by FDA
Immunome announced the FDA has accepted its New Drug Application, or NDA, for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, or GSI, for the treatment of adults with desmoid tumors. The FDA
CENTRAL_BANK | Jul 08, 2026, 11:33 AM UTC
L
Immunome Insider Sold Shares Worth $2,412,522, According to a Recent SEC Filing
() -- Isaac Barchas, Director, on July 06, 2026, sold 100,000 shares in Immunome (IMNM) for $2,412,522. Following the Form 4 filing with the SEC, Barchas has control over a total of 211,763 common shares of the company,
REGULATION | Jul 08, 2026, 07:34 AM UTC
L
Immunome Insider Sold Shares Worth $1,244,331, According to a Recent SEC Filing
() -- Robert Lechleider, Chief Medical Officer, on July 02, 2026, sold 55,000 shares in Immunome (IMNM) for $1,244,331. Following the Form 4 filing with the SEC, Lechleider has control over a total of 15,805 common share
REGULATION | Jul 07, 2026, 09:48 PM UTC